Sermorelin
A short analog of growth hormone–releasing hormone, formerly approved by the FDA as Geref.
Previously FDA-approved as Geref, which was discontinued in 2008 for business reasons. Today it is available only by prescription through a licensed provider.
What it is
Sermorelin is a short analog of growth hormone–releasing hormone (GHRH): the first 29 amino acids of the natural hormone, the part that does the signaling. It prompts the pituitary to release growth hormone.
Approval history
Sermorelin was approved in the U.S. as Geref, made by EMD Serono, and used for growth hormone deficiency in children. EMD Serono stopped selling it in 2008 for business reasons, and in 2013 the FDA confirmed the brand was not withdrawn for reasons of safety or effectiveness.
How it has been studied
It has been studied mainly in endocrine research on the growth hormone axis, including how the pituitary responds to GHRH signaling.
How to get it
Today sermorelin is available only by prescription, prepared by licensed compounding pharmacies. Anyone interested in it as a treatment should talk to a licensed medical provider.
Further reading
Search the primary literature and registered studies for Sermorelin on independent research databases. LNK is not affiliated with these sources and does not endorse their conclusions.